• レポートコード:D0JU09026 • 出版社/出版日:Transparency Market Research / 2020年1月8日 • レポート形態:英文、PDF、232ページ • 納品方法:Eメール • 産業分類:医療 |
Single User | ¥857,660 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,301,660 (USD8,795) | ▷ お問い合わせ |
Corporate License | ¥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、バイオシミラーの世界市場について調査・分析し、序論、仮定、調査手法、エグゼクティブサマリー、市場動向、市場概要、製品別(組換グリコシル化タンパク質[モノクローナル抗体、エリスロポエチン、その他]、組換非グリコシル化タンパク質[インスリン、顆粒球コロニー刺激因子、組換ヒト成長因子、インターフェロン]、組換ペプチド)分析、適応症別(慢性疾患、腫瘍学、自己免疫疾患、感染症、血液疾患、成長ホルモン欠乏症、その他)分析、地域別分析、競争状況などの構成でお届けいたします。 ・序論 ・仮定 ・調査手法 ・エグゼクティブサマリー ・市場動向 ・市場概要 ・バイオシミラーの世界市場:製品別(組換グリコシル化タンパク質[モノクローナル抗体、エリスロポエチン、その他]、組換非グリコシル化タンパク質[インスリン、顆粒球コロニー刺激因子、組換ヒト成長因子、インターフェロン]、組換ペプチド) ・バイオシミラーの世界市場:適応症別(慢性疾患、腫瘍学、自己免疫疾患、感染症、血液疾患、成長ホルモン欠乏症、その他) ・バイオシミラーの世界市場:地域別 ・競争状況 |
Biosimilars Market – Scope of the Report
TMR’S report on the global biosimilars market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period of 2019 to 2027. The report provides the overall market revenue of the global biosimilars market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global biosimilars market for the forecast period.
The report has been prepared after an extensive research. Primary research involves bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global biosimilars market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global biosimilars market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global biosimilars market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global biosimilars market. The next section of the global biosimilars report highlights the USPs, which include regulatory scenarios for biosimilars globally, Biosimilars pipeline analysis, and potential product launches in the global biosimilars market.
The report delves into the competitive landscape of the global biosimilars market. Key players operating in the global biosimilars market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global biosimilars market report.
Key Questions Answered in Biosimilars Market Report
What is the sales/revenue generated by biosimilar products across all regions during the forecast period?
What are the key trends in the biosimilars market?
What are the major drivers, restraints, and opportunities in the market?
In which region is the biosimilars market set to expand at the fastest CAGR during the forecast period?
Which segment will have the highest revenue globally in 2027 and which product segment will expand at the fastest CAGR during the forecast period?
Biosimilars Market – Research Objectives and Research Approach
The comprehensive report on the global biosimilars market begins with an overview of the said market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of this study and healthcare compliances laid down by accredited agencies in the purview of research in the biosimilars market. It is followed by market introduction, market dynamics, and an overview of the biosimilars market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the biosimilars market. The next section of the biosimilars report highlights the USPs, which include regulatory scenarios for biosimilars globally, biosimilars pipeline analysis, and key product launches in the global market.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
Revenue generated by key biosimilars market manufacturers have been mapped to ascertain the size of the global biosimilars market in terms of value. The forecast presented here assesses the total revenue generated in the biosimilars market. In order to provide an accurate forecast, we initiated by sizing up the current biosimilars market with the help of the parent market.
The report analyzes the biosimilars market in terms of product, indication, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the biosimilars market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Acronyms
3. Research Methodology
4. Executive Summary: Global Biosimilars Market
5. Market Overview
5.1. Definition
5.2. Market Indicators
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunities
6. Market Outlook
6.1. Global Biosimilars Market Analysis and Forecast, 2017–2027
6.2. Global Biosimilars Market Outlook
6.3. Entry Barriers to Biosimilars Market
6.4. Factors Driving the Adoption of Biosimilars
6.5. Pipeline Analysis
6.6. Regulatory Scenario Assessment
6.7. Key Industry Developments
7. Global Biosimilars Market Analysis and Forecast, by Product
7.1. Introduction
7.2. Biosimilars Market Value Forecast, by Product, 2017–2027
7.2.1. Recombinant Glycosylated Proteins
7.2.1.1. Monoclonal Antibodies
7.2.1.2. Erythropoietin
7.2.1.3. Others
7.2.2. Recombinant Non-glycosylated Proteins
7.2.2.1. Insulin
7.2.2.2. Granulocyte Colony Stimulating Factor
7.2.2.3. Recombinant Human Growth Factor
7.2.2.4. Interferons
7.2.3. Recombinant Peptides
7.3. Market Attractiveness, by Product
8. Global Biosimilars Market Analysis and Forecast, by Indication
8.1. Introduction
8.2. Biosimilars Market Value Forecast, by Indication, 2017–2027
8.2.1. Chronic Diseases
8.2.2. Oncology
8.2.3. Autoimmune Diseases
8.2.4. Infectious Diseases
8.2.5. Blood Disorders
8.2.6. Growth Hormone Deficiency
8.2.7. Others
8.3. Market Attractiveness By Material
9. Global Biosimilars Market Analysis and Forecast, by Region
9.1. Regional Outlook
9.2. Global Scenario
9.3. Introduction
9.4. Biosimilars Market Value Forecast, by Region
9.4.1. North America
9.4.2. Europe
9.4.3. Asia Pacific
9.4.4. Latin America
9.4.5. Middle East & Africa
9.5. Market Attractiveness, by Region
10. North America Biosimilars Market Analysis and Forecast
10.1. Key Findings
10.2. North America Biosimilars Market Value Forecast, by Product, 2017–2027
10.2.1. Recombinant Glycosylated Proteins
10.2.1.1. Monoclonal Antibodies
10.2.1.2. Erythropoietin
10.2.1.3. Others
10.2.2. Recombinant Non-glycosylated Proteins
10.2.2.1. Insulin
10.2.2.2. Granulocyte Colony Stimulating Factor
10.2.2.3. Recombinant Human Growth Factor
10.2.2.4. Interferons
10.2.3. Recombinant Peptides
10.3. North America Biosimilars Market Value Forecast, by Indication, 2017–2027
10.3.1. Chronic Diseases
10.3.2. Oncology
10.3.3. Autoimmune Diseases
10.3.4. Infectious Diseases
10.3.5. Blood Disorders
10.3.6. Growth Hormone Deficiency
10.3.7. Others
10.4. North America Biosimilars Market Value Forecast, by Country, 2017–2027
10.4.1. U.S.
10.4.2. Canada
10.5. North America Biosimilars Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Indication
10.5.3. By Country
11. Europe Biosimilars Market Analysis and Forecast
11.1. Key Findings
11.2. Europe Biosimilars Market Value Forecast, by Product, 2017–2027
11.2.1. Recombinant Glycosylated Proteins
11.2.1.1. Monoclonal Antibodies
11.2.1.2. Erythropoietin
11.2.1.3. Others
11.2.2. Recombinant Non-glycosylated Proteins
11.2.2.1. Insulin
11.2.2.2. Granulocyte Colony Stimulating Factor
11.2.2.3. Recombinant Human Growth Factor
11.2.2.4. Interferons
11.2.3. Recombinant Peptides
11.3. Europe Biosimilars Market Value Forecast, by Indication, 2017–2027
11.3.1. Chronic Diseases
11.3.2. Oncology
11.3.3. Autoimmune Diseases
11.3.4. Infectious Diseases
11.3.5. Blood Disorders
11.3.6. Growth Hormone Deficiency
11.3.7. Others
11.4. Europe Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2027
11.4.1. U.K.
11.4.2. Germany
11.4.3. France
11.4.4. Italy
11.4.5. Spain
11.4.6. Rest of Europe
11.5. Europe Biosimilars Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Indication
11.5.3. By Country/Sub-region
12. Asia Pacific Biosimilars Market Analysis and Forecast
12.1. Key Findings
12.2. Asia Pacific Biosimilars Market Value Forecast, by Product, 2017–2027
12.2.1. Recombinant Glycosylated Proteins
12.2.1.1. Monoclonal Antibodies
12.2.1.2. Erythropoietin
12.2.1.3. Others
12.2.2. Recombinant Non-glycosylated Proteins
12.2.2.1. Insulin
12.2.2.2. Granulocyte Colony Stimulating Factor
12.2.2.3. Recombinant Human Growth Factor
12.2.2.4. Interferons
12.2.3. Recombinant Peptides
12.3. Asia Pacific Biosimilars Market Value Forecast, by Indication, 2017–2027
12.3.1. Chronic Diseases
12.3.2. Oncology
12.3.3. Autoimmune Diseases
12.3.4. Infectious Diseases
12.3.5. Blood Disorders
12.3.6. Growth Hormone Deficiency
12.3.7. Others
12.4. Asia Pacific Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2027
12.4.1. China
12.4.2. India
12.4.3. Japan
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Biosimilars Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Indication
12.5.3. By Country/Sub-region
13. Latin America Biosimilars Market Analysis and Forecast
13.1. Key Findings
13.2. Latin America Biosimilars Market Value Forecast, by Product, 2017–2027
13.2.1. Recombinant Glycosylated Proteins
13.2.1.1. Monoclonal Antibodies
13.2.1.2. Erythropoietin
13.2.1.3. Others
13.2.2. Recombinant Non-glycosylated Proteins
13.2.2.1. Insulin
13.2.2.2. Granulocyte Colony Stimulating Factor
13.2.2.3. Recombinant Human Growth Factor
13.2.2.4. Interferons
13.2.3. Recombinant Peptides
13.3. Latin America Biosimilars Market Value Forecast, by Indication, 2017–2027
13.3.1. Chronic Diseases
13.3.2. Oncology
13.3.3. Autoimmune Diseases
13.3.4. Infectious Diseases
13.3.5. Blood Disorders
13.3.6. Growth Hormone Deficiency
13.3.7. Others
13.4. Latin America Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2027
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Biosimilars Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Indication
13.5.3. By Country/Sub-region
14. Middle East & Africa Biosimilars Market Analysis and Forecast
14.1. Key Findings
14.2. Middle East & Africa Biosimilars Market Value Forecast, by Product, 2017–2027
14.2.1. Recombinant Glycosylated Proteins
14.2.1.1. Monoclonal Antibodies
14.2.1.2. Erythropoietin
14.2.1.3. Others
14.2.2. Recombinant Non-glycosylated Proteins
14.2.2.1. Insulin
14.2.2.2. Granulocyte Colony Stimulating Factor
14.2.2.3. Recombinant Human Growth Factor
14.2.2.4. Interferons
14.2.3. Recombinant Peptides
14.3. Middle East & Africa Biosimilars Market Value Forecast, by Indication, 2017–2027
14.3.1. Chronic Diseases
14.3.2. Oncology
14.3.3. Autoimmune Diseases
14.3.4. Infectious Diseases
14.3.5. Blood Disorders
14.3.6. Growth Hormone Deficiency
14.3.7. Others
14.4. Middle East & Africa Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2027
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East & Africa
14.5. Middle East & Africa Biosimilars Market Attractiveness Analysis
14.5.1. By Product
14.5.2. By Indication
14.5.3. By Country/Sub-region
15. Competition Landscape
15.1. Competition Matrix
15.2. Market Share Analysis, by Company, 2018
15.3. Company Profiles
15.3.1. Pfizer, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Intas Pharmaceuticals Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Biocon
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Dr. Reddy’s Laboratories Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Teva Pharmaceutical Industries Ltd.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Sandoz International GmbH (A Novartis Division)
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Celltrion Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Amgen, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. STADA Arzneimittel AG
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
15.3.10. Apotex Inc. (Apobiologix)
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Strategic Overview
15.3.10.5. SWOT Analysis
List of TablesTable 01: Pipeline Analysis – Biosimilars
Table 02: Global Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 03: Global Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027
Table 04: Global Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027
Table 05: Global Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 06: Global Biosimilars Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 07: North America Biosimilars Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 08: North America Biosimilars Market Value (US$ Mn) Forecast, by Product Type, 2017–2027
Table 09: North America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027
Table 10: North America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027
Table 11: North America Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 12: Europe Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 13: Europe Biosimilars Market Value (US$ Mn) Forecast, by Product Type, 2017–2027
Table 14: Europe Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027
Table 15: Europe Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027
Table 16: Europe Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 17: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 18: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 19: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027
Table 20: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027
Table 21: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 22: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 23: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 24: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027
Table 25: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027
Table 26: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 27: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 28: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 29: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027
Table 30: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027
Table 31: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027